Claudio M. Anasetti

Claudio M. Anasetti's AcademicInfluence.com Rankings

Claudio M. Anasetti

Philosophy

#5401

World Rank

#8182

Historical Rank

Logic

#2687

World Rank

#3714

Historical Rank

philosophy Degrees

Claudio M. Anasetti

Biology

#7213

World Rank

#10099

Historical Rank

Immunology

#385

World Rank

#400

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Claudio M. Anasetti's Degrees

Doctorate Medicine Stanford University

Why Is Claudio M. Anasetti Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Claudio M. Anasetti's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. (2007) (1136)
Chronic graft-versus-host disease and other late complications of bone marrow transplantation. (1991) (738)
Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. (2004) (701)
Peripheral-blood stem cells versus bone marrow from unrelated donors. (2012) (698)
Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. (1989) (667)
Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. (2001) (652)
Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. (1989) (629)
Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes (1992) (627)
Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. (1998) (625)
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. (2004) (620)
Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. (2000) (620)
Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. (1990) (592)
Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. (2000) (547)
Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1 (1993) (511)
Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. (1998) (496)
Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissio (2003) (467)
Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. (1989) (428)
A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. (1990) (402)
Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. (1992) (399)
Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. (1997) (392)
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. (2003) (364)
Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. (1997) (350)
Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. (2003) (346)
Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. (1995) (345)
Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. (1991) (340)
Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. (1990) (333)
Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. (1996) (332)
Human Cytomegalovirus (CMV)-Induced Memory-like NKG2C+ NK Cells Are Transplantable and Expand In Vivo in Response to Recipient CMV Antigen (2012) (321)
Transplantation of Allogeneic Peripheral Blood Stem Cells Mobilized by Recombinant Human Granulocyte Colony Stimulating Factor (1996) (320)
Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. (1994) (311)
Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. (2001) (311)
The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. (1995) (287)
Quality of life after allogeneic hematopoietic cell transplantation. (2009) (280)
Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. (1988) (279)
Duration of immunosuppressive treatment for chronic graft-versus-host disease. (2004) (272)
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. (2002) (269)
Limits of HLA mismatching in unrelated hematopoietic cell transplantation. (2004) (265)
Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. (1991) (265)
Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. (2002) (253)
The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. (2006) (249)
Unrelated donor marrow transplantation in children. (1995) (246)
Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. (1997) (244)
Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. (2014) (241)
Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. (2001) (235)
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. (2017) (234)
Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. (2000) (234)
The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. (2007) (233)
Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. (1993) (232)
The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. (2016) (220)
Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. (2017) (216)
Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. (2014) (215)
Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. (2007) (208)
Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. (1993) (204)
Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. (2002) (203)
Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. (2011) (201)
HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. (2011) (201)
Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience (2000) (198)
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. (2003) (197)
Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. (2000) (195)
SIROLIMUS (RAPAMYCIN) FOR THE TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE1 (2001) (182)
Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. (2008) (179)
Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. (1994) (177)
Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. (2007) (169)
Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. (1997) (163)
A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. (2002) (158)
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. (2009) (156)
Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice. (2011) (150)
Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. (2004) (150)
The biological significance of HLA‐DP gene variation in haematopoietic cell transplantation (2001) (149)
Monocytes express high amounts of Notch and undergo cytokine specific apoptosis following interaction with the Notch ligand, Delta-1. (2000) (149)
FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. (1996) (146)
The Notch ligand, Delta-1, inhibits the differentiation of monocytes into macrophages but permits their differentiation into dendritic cells. (2001) (139)
Allogeneic hematopoietic stem cell transplantation for myelofibrosis. (2003) (136)
Multiple mismatches at the low expression HLA loci DP, DQ, and DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation. (2013) (136)
5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation (2010) (135)
Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. (1997) (130)
A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. (1996) (129)
Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. (1993) (127)
Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. (2000) (126)
Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. (2001) (124)
Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome. (1990) (124)
Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. (2002) (123)
A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. (2005) (123)
Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. (1991) (122)
Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. (1996) (121)
Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly. (2011) (121)
Graft-v-host disease is associated with autoimmune-like thrombocytopenia. (1989) (119)
Thalidomide for treatment of patients with chronic graft-versus-host disease. (2000) (118)
Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS‐related acute myeloid leukaemia (1996) (117)
CD28 Controls Differentiation of Regulatory T Cells from Naive CD4 T Cells1 (2008) (115)
Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research. (2005) (114)
Late complications of allogeneic and autologous marrow transplantation. (1992) (113)
Human herpesvirus 6 reactivation and encephalitis in allogeneic bone marrow transplant recipients. (2001) (111)
Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program (1993) (111)
Definition of HLA-DQ as a transplantation antigen. (1996) (108)
Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. (1997) (108)
Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. (1996) (106)
T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease. (2010) (105)
Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation (2002) (105)
Health‐related quality of life following haematopoietic cell transplantation: patient education, evaluation and intervention (2010) (105)
Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors. (2016) (104)
Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. (1996) (104)
Hematopoietic stem cell transplants from unrelated donors (1997) (103)
Graft‐versus‐host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long‐term follow‐up of a controlled trial (1989) (102)
Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the National Marrow Donor Program (2000) (102)
What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants ? (1990) (102)
CD28-Specific Antibody Prevents Graft-Versus-Host Disease in Mice1 (2000) (101)
A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients. (1999) (101)
Evaluation of the functional assessment of cancer therapy cognitive scale with hematopoietic stem cell transplant patients. (2007) (100)
Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation (2003) (98)
A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. (2010) (98)
Alloantigen presenting capacity, T cell alloreactivity and NK function of G-CSF-mobilized peripheral blood cells (1998) (97)
Second allogeneic transplantation after failure of first autologous transplantation. (2000) (93)
Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. (1995) (92)
Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. (1994) (91)
National Marrow Donor Program HLA-matching guidelines for unrelated marrow transplants. (2003) (90)
Association between pretransplant interferon-α and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase (1998) (90)
Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy. (1999) (90)
Marrow transplantation for severe aplastic anemia. Long-term outcome in fifty "untransfused" patients. (1986) (89)
Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors (2002) (89)
Antigen‐dependent suppression of alloresponses by Foxp3‐induced regulatory T cells in transplantation (2005) (89)
High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. (1993) (89)
Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial. (2016) (88)
Non-Fc Receptor-Binding Humanized Anti-CD3 Antibodies Induce Apoptosis of Activated Human T Cells1 (2000) (85)
“Superhumanized” Antibodies: Reduction of Immunogenic Potential by Complementarity-Determining Region Grafting with Human Germline Sequences: Application to an Anti-CD281 (2002) (85)
A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation (2012) (85)
Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. (2006) (85)
Role of CD28 in acute graft-versus-host disease. (1998) (84)
Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. (2016) (84)
Strong CD28 costimulation suppresses induction of regulatory T cells from naive precursors through Lck signaling. (2010) (83)
Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization (2013) (83)
Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. (2001) (82)
HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. (1999) (82)
Role of plasmacytoid dendritic cells in immunity and tolerance after allogeneic hematopoietic stem cell transplantation. (2003) (78)
Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality. (2013) (78)
The role of HLA-DPB1 disparity in the development of acute graft-versus-host disease following unrelated donor marrow transplantation (1993) (78)
Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature (2007) (77)
Allogeneic marrow transplantation for aplastic anaemia associated with dyskeratosis congenita (1996) (76)
Tumor interferon signaling and suppressive myeloid cells associate with CAR T cell failure in large B cell lymphoma. (2021) (75)
State of the art review: HLA matching and outcome of unrelated donor umbilical cord blood transplants. (2008) (74)
Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells. (1997) (74)
Stemness of B-cell Progenitors in Multiple Myeloma Bone Marrow (2012) (74)
Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. (1997) (72)
Sirolimus for treatment of steroid-refractory acute graft-versus-host disease (2010) (72)
Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donors. (1994) (71)
CD28 ligation induces transplantation tolerance by IFN-gamma-dependent depletion of T cells that recognize alloantigens. (2004) (70)
Induction of calcium flux and enhancement of cytolytic activity in natural killer cells by cross-linking of the sheep erythrocyte binding protein (CD2) and the Fc-receptor (CD16). (1987) (70)
Decreased rejection and improved survival of first and second marrow transplants for severe aplastic anemia (a 26-year retrospective analysis). (1998) (70)
A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. (2005) (70)
Unrelated donor or autologous marrow transplantation for treatment of acute leukemia. (1994) (70)
Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients (1998) (70)
Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201. (2014) (68)
Cell cycle control of apoptosis in human leukemic T cells. (1995) (67)
Immunosuppressive therapy of aplastic anemia: results of a prospective, randomized trial of antithymocyte globulin (ATG), methylprednisolone, and oxymetholone to ATG, very high-dose methylprednisolone, and oxymetholone. (1992) (67)
Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. (2001) (67)
The role of HLA-DPB1 disparity in the development of acute graft-versus-host disease following unrelated donor marrow transplantation. (1993) (66)
Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience (2004) (65)
Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. (2004) (65)
Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission. (2011) (65)
The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality (2011) (64)
Phase II trial of recombinant human granulocyte-macrophage colony-stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors. (1992) (64)
Tissue typing in support of unrelated hematopoietic cell transplantation. (2003) (64)
Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. (2002) (63)
Changing trends in marrow transplantation for aplastic anemia. (1992) (63)
Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review (2012) (62)
Advances in transplantation tolerance (2001) (62)
Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. (2002) (61)
Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation (1998) (61)
Effect of HLA mismatches on the outcome of hematopoietic transplants. (1999) (60)
Practice variation in physician referral for allogeneic hematopoietic cell transplantation (2012) (60)
Expression of CD86 on Human Marrow CD34+ Cells Identifies Immunocompetent Committed Precursors of Macrophages and Dendritic Cells (1998) (60)
Adoptive Transfer of Tc1 or Tc17 Cells Elicits Antitumor Immunity against Established Melanoma through Distinct Mechanisms (2013) (60)
Role of mitogen‐activated protein kinases in activation‐induced apoptosis of T cells (1999) (60)
Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. (2017) (59)
Bone Marrow Stroma Confers Resistance to Apo2 Ligand/TRAIL in Multiple Myeloma in Part by Regulating c-FLIP1 (2008) (59)
Bone marrow transplantation for severe aplastic anemia from genotypically HLA-nonidentical relatives. An update of the Seattle experience. (1996) (59)
Dynamic change and impact of myeloid-derived suppressor cells in allogeneic bone marrow transplantation in mice. (2013) (58)
TREATMENT OF ACUTE GRAFT‐VERSUS‐HOST DISEASE WITH A NONMITOGENIC ANTI‐CD3 MONOCLONAL ANTIBODY (1992) (58)
Glucocorticoid-refractory acute graft-versus-host disease. (2010) (58)
Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. (2009) (57)
The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia. (1998) (57)
Evaluation of a CD5-specific immunotoxin for treatment of acute graft- versus-host disease after allogeneic marrow transplantation (1996) (55)
A clinical phase I/II study of recombinant human interleukin-1 receptor in glucocorticoid-resistant graft-versus-host disease. (1996) (55)
Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities (2000) (55)
Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation (2018) (54)
Bone marrow transplantation for chronic myelogenous leukemia. (1995) (53)
Induction of specific nonresponsiveness in unprimed human T cells by anti-CD3 antibody and alloantigen (1990) (52)
Marrow transplantation from unrelated volunteer donors. (1995) (51)
Role of the mixed lymphocyte culture reaction in predicting acute graft-versus-host disease after marrow transplants from haploidentical and unrelated donors. (1993) (51)
Impending challenges in the hematopoietic stem cell transplantation physician workforce. (2009) (50)
Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. (2012) (49)
Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia (2010) (49)
Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. (1996) (49)
Beta2 integrins separate graft-versus-host disease and graft-versus-leukemia effects. (2008) (49)
The National Marrow Donor Program's Symposium on Hematopoietic Cell Transplantation in 2020: a health care resource and infrastructure assessment. (2012) (47)
Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. (2000) (46)
Expression of CD86 on human marrow CD34(+) cells identifies immunocompetent committed precursors of macrophages and dendritic cells. (1998) (46)
Cyclophosphamide plus ATG conditioning is insufficient for sustained hematopoietic reconstitution in patients with severe aplastic anemia transplanted with marrow from HLA-A, B, DRB matched unrelated donors. (1994) (46)
Human regulatory T cells against minor histocompatibility antigens: ex vivo expansion for prevention of graft-versus-host disease. (2013) (45)
9 Allografting for chronic myeloid leukaemia (1997) (44)
National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide (2021) (44)
Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia [letter] (1994) (44)
CD4+ T cell STAT3 phosphorylation precedes acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response (2015) (43)
CD8+ Tregs promote GVHD prevention and overcome the impaired GVL effect mediated by CD4+ Tregs in mice (2016) (42)
Recent decrease in acute graft-versus-host disease in children with leukemia receiving unrelated donor bone marrow transplants. (2009) (42)
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007. (2007) (42)
Alloantigen Presenting Function of Normal Human CD34+ Hematopoietic Cells (1996) (42)
Efficient and selective prevention of GVHD by antigen-specific induced Tregs via linked-suppression in mice. (2011) (41)
Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia [letter] (1992) (41)
Abundant c-Fas-associated death domain-like interleukin-1-converting enzyme inhibitory protein expression determines resistance of T helper 17 cells to activation-induced cell death. (2009) (41)
Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice. (2013) (40)
Time to consider HPV vaccination after allogeneic stem cell transplantation. (2010) (40)
Comparison of morbidity and mortality after marrow transplantation from HLA-genotypically identical siblings and HLA-phenotypically identical unrelated donors. (1994) (39)
Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function (2017) (39)
Back to the future: mismatched unrelated donor, haploidentical related donor, or unrelated umbilical cord blood transplantation? (2012) (39)
Evaluation of the mixed lymphocyte culture (MLC) assay as a method for selecting unrelated donors for marrow transplantation. (1996) (39)
CD28 Signal Enhances Apoptosis of CD8 T Cells After Strong TCR Ligation 1 (2003) (38)
ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation. (2011) (38)
Randomized Multicenter Trial of Sirolimus vs. Prednisone as Initial Therapy for Standard Risk Acute GVHD: BMT CTN 1501. (2019) (38)
Anti-CD3ε F(ab′)2 Prevents Graft-Versus-Host Disease by Selectively Depleting Donor T Cells Activated by Recipient Alloantigens1 (2001) (37)
Initial therapy for chronic myelogenous leukemia: playing the odds. (1998) (37)
Minimal-change nephrotic syndrome after cyclosporine withdrawal in a marrow transplant recipient. (1995) (37)
Human large granular lymphocytes express high affinity receptors for murine monoclonal antibodies of the IgG3 subclass. (1987) (37)
Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia (2001) (36)
Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. (1998) (36)
HLA matching in hematopoietic cell transplantation. (2000) (36)
A pilot study of low‐dose cyclosporin for graft‐versus‐host prophylaxis in marrow transplantation (1992) (36)
What are the most important donor and recipient factors affecting the outcome of related and unrelated allogeneic transplantation? (2008) (36)
Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel (2020) (35)
T-bet Is Critical for the Development of Acute Graft-versus-Host Disease through Controlling T Cell Differentiation and Function (2012) (35)
What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? (1990) (35)
Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation (2000) (34)
Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine? (1997) (34)
Long term effects and quality of life in children and adults after marrow transplantation. (1989) (33)
Prevention of lethal acute GVHD with an agonistic CD28 antibody and rapamycin. (2005) (33)
Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia. (2011) (33)
Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation. (2009) (33)
Treatment of malignancy with unmodified antibody. (1987) (33)
Regulatory T-Cell Therapy for Graft-versus-host Disease. (2016) (32)
Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation. (2000) (32)
Hematopoietic cell transplantation in 2020: summary of year 2 recommendations of the National Marrow Donor Program's System Capacity Initiative. (2013) (32)
STAT5 polarization promotes iTregs and suppresses human T‐cell alloresponses while preserving CTL capacity (2014) (32)
The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase. (2001) (32)
Marrow transplants from HLA matched unrelated donors: an NMDP update and the Seattle experience. (1994) (32)
Growth and development after bone marrow transplantation. (1989) (31)
Variation in management of immune suppression after allogeneic hematopoietic cell transplantation. (2011) (31)
Unrelated donor marrow transplants for severe acquired aplastic anemia. (1992) (31)
Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy. (2015) (31)
Opposing effects of ICOS on graft-versus-host disease mediated by CD4 and CD8 T cells. (2006) (31)
Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts. (1999) (31)
T cell alloreactivity induced by normal G-CSF-mobilized CD34+ blood cells (1998) (30)
Autologous bone marrow transplantation for acute lymphoblastic leukemia. (1993) (30)
Plasmacytoid dendritic cells: do they have a role in immune responses after hematopoietic cell transplantation? (2002) (30)
Ustekinumab demonstrates activity in glucocorticoid-refractory acute GVHD (2012) (30)
Donors other than HLA-identical siblings. (1989) (30)
IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation (2017) (30)
Bortezomib restores stroma‐mediated APO2L/TRAIL apoptosis resistance in multiple myeloma (2010) (30)
Treatment of acute graft-versus-host disease with anti-CD3 monoclonal antibodies. (1988) (30)
Prophylaxis of graft-versus-host disease by administration of the murine anti-IL-2 receptor antibody 2A3. (1991) (30)
Kinetics of immune cell reconstitution predict survival in allogeneic bone marrow and G-CSF-mobilized stem cell transplantation. (2019) (30)
Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature (2007) (28)
Marrow transplant experience for children with severe aplastic anemia. (1994) (28)
Dysglycemia following glucocorticoid therapy for acute graft-versus-host disease adversely affects transplantation outcomes. (2010) (28)
Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans (2006) (28)
Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease. (2010) (27)
Health-related quality of life of bone marrow versus peripheral blood stem cell donors: a prespecified subgroup analysis from a phase III RCT-BMTCTN protocol 0201. (2014) (27)
Have we improved in preventing and treating acute graft-versus-host disease? (2011) (26)
Infliximab for managing steroid-refractory acute graft-versus-host disease. (2009) (26)
Hematopoietic Cell Transplantation from HLA Partially Matched Related Donors (2007) (26)
T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome. (2012) (26)
Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease (2010) (26)
Trends in transplantation of hematopoietic stem cells from unrelated donors. (2001) (25)
Opposing Effects of ICOS on Graft-versus-Host Disease Mediated by CD4 and CD8 T Cells1 (2006) (25)
Genomics of unrelated-donor hematopoietic cell transplantation. (2001) (25)
Peripheral-blood versus bone marrow stem cells. (2013) (24)
Graft-versus-host disease prophylaxis with methotrexate/cyclosporine in children with severe aplastic anemia treated with cyclophosphamide and HLA-identical marrow grafts [letter] (1991) (24)
Allografting for chronic myeloid leukaemia. (1997) (24)
LBH589 enhances T cell activation in vivo and accelerates graft-versus-host disease in mice. (2012) (24)
Allogeneic hematopoietic stem‐cell engraftment and graft failure (1999) (23)
Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. (2011) (23)
Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity (2011) (23)
Unrelated and HLA‐Nonidentical Related Donor Marrow Transplantation forThalassemia and Leukemia: A Combined Report from the Seattle Marrow Transplant Team and the International Bone Marrow Transplant Registry a (1998) (23)
Alloantigen Affinity and CD4 Help Determine Severity of Graft-versus-Host Disease Mediated by CD8 Donor T Cells1 (2006) (23)
Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase III Blood and Marrow Transplant Clinical Trials Network Protocol 0201. (2016) (23)
Voriconazole Provides Effective Prophylaxis for Invasive Fungal Infection in Patients Receiving Glucocorticoid Therapy for Graft-Versus-Host Disease (2009) (23)
Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: A prospective, randomized trial (1997) (23)
Hematopoietic cell transplantation for chronic lymphocytic leukemia: an evolving concept. (2007) (23)
T regulatory cells as an immunotherapy for transplantation (2006) (23)
Marrow transplantation from unrelated volunteer donors. (1995) (23)
Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia (2011) (22)
Visualization, fate, and pathogenicity of antigen-specific CD8+ T cells in the graft-versus-host reaction. (1999) (22)
Lck Is Required for Activation-Induced T Cell Death after TCR Ligation with Partial Agonists1 (2004) (22)
High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. (1995) (22)
Marrow transplantation for severe aplastic anemia and thalassemia major. (1991) (22)
HLAs and risk of acute graft-vs.-host disease after marrow transplantation from an HLA-identical sibling. (1998) (22)
In vivo IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation (2017) (22)
The Role of Age in Neurocognitive Functioning among Adult Allogeneic Hematopoietic Cell Transplant Recipients. (2017) (22)
Anti-CD3 epsilon F(ab')2 prevents graft-versus-host disease by selectively depleting donor T cells activated by recipient alloantigens. (2001) (21)
A Limited Sampling Schedule to Estimate Individual Pharmacokinetic Parameters of Fludarabine in Hematopoietic Cell Transplant Patients (2009) (21)
Marrow transplantation from unrelated donors (1995) (21)
c‐Rel is an essential transcription factor for the development of acute graft‐versus‐host disease in mice (2013) (20)
Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease (2015) (20)
HY-Specific Induced Regulatory T Cells Display High Specificity and Efficacy in the Prevention of Acute Graft-versus-Host Disease (2015) (20)
Improving availability and safety of unrelated donor transplants (2000) (19)
Bortezomib salvage followed by a Phase I/II study of bortezomib plus high‐dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma (2012) (19)
Blood and marrow transplant clinical trials network state of the Science Symposium 2014. (2015) (18)
FK 506-based immunosuppression for prevention of graft versus host disease after unrelated donor marrow transplantation. (1995) (18)
Induction of apoptosis by anti-CD3 epsilon F(ab')2 in antigen receptor transgenic murine T cells activated by specific peptide. (1996) (18)
Selection of an unrelated donor for marrow transplantation facilitated by the molecular characterization of a novel HLA-A allele. (1993) (18)
Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor. (1996) (18)
Enhancement of susceptibility to Fas-mediated apoptosis of TH1 cells by nonmitogenic anti-CD3epsilon F(ab')2. (2000) (18)
Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids (2011) (18)
Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia. (1994) (18)
Identification of DPB1 Permissive Unrelated Donors Is Highly Likely. (2017) (18)
Transplantation of hematopoietic stem cells from alternate donors in acute myelogenous leukemia (2000) (17)
Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity (2018) (17)
Generic immunosuppressants in hematopoietic cell transplantation. (2011) (17)
Evaluation of pretransplant donor anti-recipient cytotoxic and helper T lymphocyte responses as correlates of acute graft-vs.-host disease and survival after unrelated marrow transplantation. (1997) (17)
Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome. (2014) (17)
Can antigen-specific regulatory T cells protect against graft versus host disease and spare anti-malignancy alloresponse? (2010) (17)
Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease. (2020) (17)
Treatment of leukemia by marrow transplantation from HLA incompatible donors. Effect of HLA-disparity on GVHD, relapse and survival. (1990) (17)
Marrow transplantation from unrelated HLA-matched volunteer donors. (1989) (17)
Thalidomide for treatment of patients with chronic graft-versus-host disease (2000) (16)
Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results. (2015) (16)
Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention (2017) (16)
Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study. (2009) (16)
Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. (1992) (16)
Marrow transplants from unrelated donors. (1995) (16)
Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications (2011) (16)
Long-term follow-up of three controlled trials comparing cyclosporine versus methotrexate for graft-versus-host disease prevention in patients given marrow grafts for leukemia [letter] (1992) (16)
Curative Therapy of Advanced Essential Thrombocythemia or Polycythemia Vera by Hemopoietic Stem Cell Transplantation (2002) (15)
Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. (2014) (15)
TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome (2017) (15)
Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement. (2019) (15)
Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes (2011) (14)
Deletion of immunosuppressive prophylaxis after marrow transplantation increases hyperacute graft-versus-host disease but does not influence chronic graft-versus-host disease or relapse in patients with advanced leukemia (1989) (14)
Effect of HLA matching on outcome of related and unrelated donor transplantation therapy for chronic myelogenous leukemia. (1998) (14)
Role of the mixed lymphocyte culture (MLC) reaction in marrow donor selection: matching for transplants from related haploidentical donors. (1994) (14)
Preparing for growth: current capacity and challenges in hematopoietic stem cell transplantation programs. (2010) (14)
Memory stem cells sustain disease (2005) (14)
Adhesion of CD16+ K cells to antibody-coated targets is mediated by CD2 and CD18 receptors. (1993) (14)
Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration (2014) (13)
Methods for assessment of graft-versus-host disease. (1998) (13)
Marrow transplants from unrelated donors. (1994) (13)
A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. (2021) (13)
Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma (2013) (13)
Donor buffy coat cell infusion after marrow transplantation for aplastic anemia. (1988) (13)
Long-term follow-up of 103 patients who received recombinant human granulocyte-macrophage colony-stimulating factor after unrelated donor bone marrow transplantation [letter] (1993) (13)
Generation of HLA-C-specific cytotoxic T cells in association with marrow graft rejection: analysis of alloimmunity by T-cell cloning and testing of T-cell-receptor rearrangements. (2001) (13)
To ablate or not to ablate? HSCs in the T cell driver's seat. (2007) (13)
Transplantation of hematopoietic stem cells (HSC). (1987) (12)
The role of T cell costimulation by CD80 in the initiation and maintenance of the immune response to human leukemia. (1999) (12)
CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. (2017) (12)
Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation. (2019) (12)
Comparison of Characteristics and Outcomes of Trial Participants and Nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Trial. (2015) (12)
Pre-Transplant 5-Azacitidine (Vidaza®) May Improve Outcome of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Myelodysplastic Syndrome (MDS). (2006) (12)
Use of alternative donors for allogeneic stem cell transplantation. (2015) (12)
Alloantigen-specific T suppressor-inducer and T suppressor-effector cells can be activated despite blocking the IL-2 receptor. (1990) (12)
Marrow transplantation from HLA partially matched relatives and unrelated donors (1995) (11)
Long-Term Comparison of Immunosuppressive Therapy with Antithymocyte Globulin to Bone Marrow Transplantation in Aplastic Anemia (1990) (11)
Alloantigen affinity and CD4 help determine severity of graft-versus-host disease mediated by CD8 donor T cells. (2006) (11)
Retrospective comparison of filgrastim plus plerixafor to other regimens for remobilization after primary mobilization failure: Clinical and economic outcomes (2012) (11)
Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting. (2013) (11)
Graft-versus-host disease prophylaxis with methotrexate/cyclosporine in children with severe aplastic anemia treated with cyclophosphamide and HLA-identical marrow grafts. (1991) (11)
Alloantigen presenting function of normal human CD34+ hematopoietic cells. (1996) (11)
Allogeneic marrow transplantation for chronic myeloid leukemia (1994) (10)
Allogeneic marrow transplantation (1993) (10)
Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission (2014) (10)
Patient Ethnicity Markedly Affects The Probability Of Finding An HLA-A, -B, -C, And DRB1 Allele Matched Unrelated Donor For Hemopoietic Cell Transplantation (2010) (10)
Hepatic veno-occlusive disease following sirolimus-based immune suppression (2018) (10)
ADVANCES IN THE PREVENTION OF GRAFT-VERSUS-HOST DISEASE AFTER HEMATOPOIETIC CELL TRANSPLANTATION (2004) (9)
Response to Recipient CMV Antigen Transplantable and Expand In Vivo in NK Cells Are + Memory-like NKG 2 C Human Cytomegalovirus ( CMV )-Induced Anasetti (2012) (9)
Selection of marrow donors for patients lacking an HLA-identical sibling. (1990) (9)
HLA homozygosity and the risk of graft-versus-host disease. (1997) (9)
Marrow transplantation from donors other than HLA identical siblings. (1990) (9)
Advances in unrelated donor hematopoietic cell transplantation. (2003) (8)
Marrow Transplants from Unrelated Donors as Treatment for Acute Leukemia (2000) (8)
Impact of infused CD34+ stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide (2021) (8)
Role of CD 28 in Acute Graft-Versus-Host Disease (1998) (8)
The Clinical Significance of Matching for Alleles at the Low Expression HLA Loci DP, DQ and DRB3/4/5 in Unrelated Hematopoietic Stem Cell Transplantation (2008) (8)
Are matched unrelated donor transplants justified for AML in CR1? (2006) (8)
Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease (2018) (8)
Metabolic reprogramming augments potency of human pSTAT3-inhibited iTregs to suppress alloreactivity. (2020) (8)
Evaluation of a Risk-Based Algorithm for the Utilization of Plerixafor As Primary Mobilization of CD34+ Cells in Autologous Hematopoietic Cell Transplant Candidates, (2011) (8)
Boosting humoral and cellular immunity to pneumococcus by vaccination before and just after autologous transplant for myeloma (2016) (8)
Increased infections and delayed CD4+ T-cell but faster B-cell Immune Reconstitution after Posttransplant Cyclophosphamide Compared to Conventional GVHD prophylaxis in Allogeneic Transplantation. (2021) (8)
Single or Multiple HLA-A, B, C or DRB1 Mismatches Limit Success of Unrelated Donor Bone Marrow Transplantation. (2006) (8)
Tolerance Associated Gene Expression following Allogeneic Hematopoietic Cell Transplantation (2012) (8)
The association of CMV with NK-cell reconstitution depends on graft source: results from BMT CTN-0201 samples. (2019) (8)
A toxicity study of trimetrexate used in combination with cyclosporine as acute graft-versus-host disease prophylaxis in HLA-mismatched, related donor bone marrow transplants. (1995) (8)
Diagnosis and Management of Leukemic and Lymphomatous Meningitis. (2017) (8)
Busulfan Area-under-the-Curve Finding Study within a Busulfan/Fludarabine (BuFlu) Conditioning Regimen before Allogeneic Hematopoietic Cell Transplantation (HCT). (2006) (8)
ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. (2021) (7)
Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. (2015) (7)
What We Have Learned and What We Need to Know (2006) (7)
Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results (2021) (7)
rhGM-CSF after allogeneic bone marrow transplantation from unrelated donors: a pilot study of cyclosporine and prednisone as graft-versus-host disease prophylaxis. (1993) (7)
Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma (2015) (7)
Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation (2017) (6)
HLA and marrow transplants from unrelated donors (1994) (6)
Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia (2020) (6)
Non-FcR-binding, humanized anti-CD3 antibody Hu291 induces apoptosis of human T cells more effectively than OKT3 and is immunosuppressive in vivo. (2000) (6)
Bim is required for T-cell allogeneic responses and graft-versus-host disease in vivo. (2012) (6)
Biomarkers to discern transplantation tolerance after allogeneic hematopoietic cell transplantation. (2010) (6)
Influence of HLA-DPB1 disparity on the development of acute graft-versus-host disease following unrelated donor marrow transplantation. (1993) (6)
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL) (2016) (6)
Larger Numbers of Donor Naïve CD8+ T-Cells and Plasmacytoid Dendritic Cell Precursors In Allogeneic BM Grafts From Unrelated Donors Are Associated with Improved Survival: Results From BMT CTN 0201 (2011) (6)
Objective and subjective physical function in allogeneic hematopoietic stem cell transplant recipients (2021) (6)
Antithymocyte Globulin (ATG) for Graft-Versus-Host-Disease (GvHD) Prophylaxis In Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (allo-HCT): a Systematic Review and Meta-Analysis. (2010) (6)
The role of the immunogenetics laboratory in marrow transplantation. (1991) (5)
Methods for assessment of graft-versus-host disease [5] (multiple letters) (1998) (5)
Antigen-dependent suppression of graft versus host disease by Foxp3-induced regulatory T cells in transplantation (2006) (5)
In VITRO Polarized TH17 Cells Induce Severe Acute Graft-Versus-Host Disease (2009) (5)
Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience (2015) (5)
T-bet Promotes Acute Graft-versus-Host Disease by Regulating Recipient Hematopoietic Cells in Mice (2016) (5)
Targeting JAK2 By Gene Knockout or Pacritinib Treatment Reduces Gvhd and Xenograft Rejection By Promoting Induced Treg Differentiation (2015) (5)
Use of Peripheral Blood Grafts Is Associated with Increased Acute and Chronic Graft-Versus-Host Disease without Improved Survival after Unrelated Donor Transplantation. (2005) (5)
Long-term follow-up of three controlled trials comparing cyclosporine versus methotrexate for graft-versus-host disease prevention in patients given marrow grafts for leukemia. (1992) (5)
Donor-derived constitutional chromosomal abnormalities after allogeneic hematopoietic cell transplantation: a single-center experience and a review of the literature (2015) (5)
Hematopoietic Cell Transplantation from Human Leukocyte Antigen Partially Matched Related Donors (2009) (5)
The 2006 BBMT Education Supplement. (2006) (5)
Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative (2020) (5)
Health-Related Quality-of-Life Among Adult Matched Unrelated Stem Cell Donors: A Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Randomized Trial of Marrow Versus PBSC Donation (2010) (5)
Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft‐versus‐host disease score (2018) (5)
330: Rituximab is Feasible to Administer to Allograft Recipients with Advanced CD20+ Malignancies and does not Affect Timely Hematopoietic Engraftment (2008) (4)
Selection of Patients With Myelodysplastic Syndrome for Allogeneic Hematopoietic Stem Cell Transplantation. (2016) (4)
Maximally Tolerated Busulfan Area Under the Concentration-Time Curve (AUC) in Combination With Fludarabine as Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation (2011) (4)
Recipient single nucleotide polymorphisms in Paneth cell antimicrobial peptide genes and acute graft‐versus‐host disease: analysis of BMT CTN‐0201 and ‐0901 samples (2018) (4)
Long-term complications of bone marrow transplantation. (1989) (4)
Advances in unrelated donor hematopoietic cell transplantation: improved matching and use of blood stem cells. (2002) (4)
Pre-B cells in agammaglobulinemia: Evidence for disease heterogeneity among affected boys (1985) (4)
Donor-Recipient Matching at the HLA-C Locus and Early Outcomes after Unrelated Umbilical Cord Blood Transplant (UCBT) (2008) (4)
Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical HCT with Post-Transplant Cyclophosphamide (2021) (4)
Expression of CD 86 on Human Marrow CD 34 1 Cells Identifies Immunocompetent Committed Precursors of Macrophages and Dendritic Cells (1998) (4)
White Paper on Measurement of Quality Outcomes (2006) (4)
Chemotherapy or allografting for young adults with high-risk ALL? (2008) (4)
Defining Competency to Empower Blood and Marrow Transplant and Cellular Immunotherapy Quality Management Professionals in Healthcare. (2019) (4)
More Infections with Transplantation of Bone Marrow, Versus Peripheral-Blood Stem Cells, from Unrelated Donors (2015) (4)
Biomarkers for GVHD prognosis. (2015) (4)
Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study. (2018) (3)
Thrombotic microangiopathy after GVHD prophylaxis with tacrolimus/sirolimus: a call for use of consensus definition in reporting. (2010) (3)
A Phase 2 Study of Bortezomib Plus High-Dose Melphalan (Mel/Vel) Conditioning for Autologous Hematopoietic Cell Transplantation In Multiple Myeloma, (2011) (3)
5 Year Results of BMT CTN 0201: Unrelated Donor Bone Marrow Is Associated with Better Psychological Well-Being and Less Burdensome Chronic Gvhd Symptoms Than Peripheral Blood (2015) (3)
304: Effect of Substituting Fludarabine and Thymoglobulin for Cyclophosphamide in Busulfan-based Conditioning Regimens on T-cell Chimerism and outcomes after Allogeneic Hematopoietic Cell Transplantation (HCT) (2008) (3)
Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap. (2017) (3)
Sirolimus Vs. Prednisone As Initial Systemic Therapy for Minnesota Standard Risk (MN-SR), Ann Arbor 1/2 Acute Graft-Vs-Host Disease (GVHD): Primary Results of the Multi-Center Randomized Phase II BMT CTN 1501 Trial (2019) (3)
Allogeneic marrow transplantation: the Seattle experience. (1989) (3)
A Phase I/II Trial Evaluating The Use Of a Histone Deacetylase Inhibitor Panobinostat (LBH589) In Addition To Glucocorticoids In Patients With Acute Graft-Versus-Host Disease (2013) (3)
Allogeneic hematopoietic cell transplantation for myelofibrosis: A 10‐year experience at single institution (2010) (3)
Comparison of Peripheral Blood Stem Cells (PBSC) to Bone Marrow (BM) for T-Replete HLA-Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide (2016) (3)
SOLE UPFRONT THERAPY WITH BECLOMETHASONE AND BUDESONIDE FOR UPPER GASTRO-INTESTINAL ACUTE GVHD: Topical therapy for upper gastrointestinal GVHD. (2020) (3)
Dual JAK2/Aurora kinase A inhibition prevents human skin graft rejection by allo‐inactivation and ILC2‐mediated tissue repair (2021) (3)
Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results (2020) (3)
Allogeneic marrow transplantation: the Seattle experience. (1993) (3)
Erratum: Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature (Bone Marrow Transplantation (2007) vol. 39 (101-107) 10.1038/sj.bmt.1705548) (2007) (3)
Marrow transplantation for severe aplastic anemia associated with exposure to quinacrine (1990) (3)
382: β2 Intergrins Separates Graft-versus-host Disease and Graft-versus-leukemia Effect (2008) (3)
Risk Factors for Graft Rejection of Marrow Transplants From HLA Haploidentical Donors (1989) (3)
A Randomized, Controlled Trial of Graft-Versus-Host Disease (GVHD) Prophylaxis Comparing Tacrolimus and Mycophenolate Mofetil to Tacrolimus and Methotrexate: Analysis of GVHD, Relapse and Survival (2009) (3)
A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention. (2021) (3)
Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap (2017) (3)
Long-term follow-up of 103 patients who received recombinant human granulocyte-macrophage colony-stimulating factor after unrelated donor bone marrow transplantation. (1993) (3)
Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia (2016) (3)
A Randomized, Controlled Trial of Graft-Versus-Host Disease (GVHD) Prophylaxis Comparing Tacrolimus and Mycophenolate Mofetil to Tacrolimus and Methotrexate: Analysis of GVHD, Relapse and Survival. (2008) (2)
Unrelated donor marrow transplantation for treatment of childhood hematologic malignancies-effect of HLA disparity and cell dose. (1999) (2)
Physical activity as a predictor of outcomes in hematopoietic stem cell transplantation (HSCT) recipients. (2015) (2)
Apheresis and transplant of hematopoietic progenitor cells (HPC) from allogeneic donors of age above 60 years (2012) (2)
Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia In First Complete Remission: A Systematic Review and Meta-Analysis (2010) (2)
Evaluation Of Patients With Myelodysplastic Syndrome (MDS) Up To Age Seventy-Five, Referred For Allogeneic Hematopoietic Cell Transplant (HCT) Including Donor Availability And HCT Outcomes (2010) (2)
The ever elusive permissive mismatch. (2012) (2)
Infections Post Transplant Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation (2003) (2)
Targeted Intravenous Busulfan Combined with Fludarabine (tBuFlu) as Conditioning Prior to Allogeneic Peripheral Blood Stem Cell Transplant: Early Results of Low Treatment Related Mortality. (2005) (2)
Retrospective Comparison Of Secondary Mobilization Strategies In Candidates For Autologous Hematopoietic Cell Transplantion With A Focus On Resource Utilization: Plerixafor+G-CSF Versus Other Regimens (2010) (2)
Impact of molecular histocompatibility typing on outcome of unrelated donor hematopoietic cell transplantation (2002) (2)
Marrow Transplants from Unrelated Donors for the Treatment of High-Risk Acute Leukemia (1998) (2)
Recent Decrease in Acute GVHD in Children with Leukemia Receiving Unrelated Donor Bone Marrow Transplants Blood Marrow (2012) (2)
Predictive facts and prevention of acute graft-versus-host disease (1988) (2)
Bortezomib Followed by a Phase I Study of Bortezomib in Combination With High-Dose Melphalan as a Preparative Regimen for Hematopoietic Cell Transplants in Patients With Primary Refractory Multiple Myeloma or Plasma Cell Leukemia (2011) (2)
Transformation of T-Cell Acute Lymphoblastic Lymphoma to Peripheral T-Cell Lymphoma: A Report of Two Cases (2018) (2)
directly or indirectly Ex vivo expansion of human Tregs specific for alloantigens presented (2011) (2)
Prior Therapy with Rituximab Correlates with Less Acute Graft-Versus-Host Disease and Better Survival in B-Cell Lymphoma Patients Who Received Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT). (2007) (2)
Allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic syndrome (2015) (2)
Sirolimus and tacrolimus binding proteins: double-edged swords for GVHD prophylaxis (2003) (2)
Transplantation Using Bone Marrow from a (very) HLA Mismatched Unrelated Donor in the Setting of Post-Transplant Cyclophosphamide Is Feasible and Expands Access to Underserved Minorities (2020) (2)
Marrow grafting for acute leukemia: results and future treatment strategies. (1990) (2)
Effect of HLA-DRB1 and DQB1 allele disparity on the development of acute graft versus host disease following unrelated donor marrow transplantation (1994) (2)
A Phase II Study of Sirolimus-Based Calcineurin Inhibitor-Free Gvhd Prophylaxis after Peripheral Blood Haploidentical Transplantation with Post-Transplant Cyclophosphamide (2020) (2)
T-Cell Costimulation and Coinhibition in Graft-Versus-Host Disease and Graft-Versus-Leukemia Effect (2019) (2)
FTY720 prevents GVHD: the host perspective (2007) (2)
Reduced-Intensity Allogeneic Bone Marrow Transplantation (2006) (1)
transplantation comparative analysis of unrelated versus matched sibling donor Allogeneic bone marrow transplantation for chronic myelogenous leukemia (2013) (1)
Body Composition Predicts for Survival in Allogeneic (allo) Hematopoietic Stem Cell Transplantation (HCT) Recipients (2016) (1)
E-rosette receptor in human lymphocytes. (1987) (1)
Visilizumab with Tacrolimus and Methotrexate for Graft-Versus-Host Disease Prevention After Allogeneic Hematopoietic Cell Transplantation From Mismatched Unrelated Donors (2016) (1)
Allogeneic marrow transplantation for myelodysplastic syndrome (MDS) using unrelated donors (URD) (1994) (1)
AgonistsCell Death after TCR Ligation with Partial Lck Is Required for Activation-Induced T (2004) (1)
Development of Zenapax®: A Humanized Anti-Tac Antibody (2019) (1)
ncreasingly Frequent Diagnosis of Acute astrointestinal Graft-versus-Host Disease after llogeneic Hematopoietic Cell Transplantation (2004) (1)
Administration of Rituximab Is Feasible and Does Not Affect Engraftment of Allograft Recipients with Advanced CD20+ Malignancies. (2007) (1)
Marrow Transplantation for Severe Aplastic Anemia (2020) (1)
Acquired Tolerance to Renal Allografts in Humans (2003) (1)
Multi-State Modeling Identifies Determinants of Successful Immune Suppression Discontinuation: Secondary Analysis of BMT CTN 0201 and 0402 Trials (2017) (1)
Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft Vs. Host Disease (2015) (1)
8.2-03 Graft-versus-host reaction, relapse and survival after HLA-nonidentical marrow transplants for malignancy (1989) (1)
Impact of a Lower Busulfan Area Under the Concentration-Time Curve (AUC) Dosing Target on Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes (2012) (1)
Recent Decrease in Acute GVHD and Increased Relapse in Children with Leukemia Receiving Unrelated Donor Bone Marrow Transplants. (2007) (1)
Selection of unrelated donors for hematopoietic cell transplantation. (2005) (1)
CD4+ T-Cell STAT3 Activity Is Increased before Acute Graft-Versus-Host Disease Onset and Its Pharmacologic Inhibition Selectively Controls Alloresponses (2014) (1)
The Anti-CD25 Antibody Daclizumab Delays Treg Reconstitution, Promotes CD4 Memory, and Does Not Prevent Acute or Chronic Gvhd After Allogeneic Stem Cell Transplantation (2012) (1)
Allogeneic and Syngeneic Marrow Transplantation for Aplastic Anemia: Overview of Seattle (1988) (1)
dendritic cells Granulocyte-colony stimulating factor mobilizes T helper 2-inducing (2013) (1)
Allogeneic Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) after Pretransplant 5-Azacitidine. (2007) (1)
TP53 and IDH2 Somatic Mutations Are Associated with Poor Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome (2015) (1)
Immunosuppressive agents for prevention of graft-versus-host disease (1995) (1)
HDAC11 Inhibits T-Cell Response to Alloantigens and Reduces Gvhd In Mice. (2010) (1)
PI3K-Independent Signaling Pathways Contribute to ICOS-Mediated T-Cell Costimulation in Acute Graft-Versus-Host Disease in Mice. (2012) (1)
HLA-Mismatch Is Associated with Worse Outcomes after Myeloablative Conditioning and Unrelated Donor Hematopoietic Cell Transplantation: A Cibmtr Analysis (2014) (1)
ASBMT committee report: white paper on measurement of quality outcomes. (2006) (1)
Response to Kawedia et al Letter to Editor in Response to the Article by McCune Et Al "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement". (2020) (1)
Association between recipient TNF rs361525 and acute GVHD: results from analysis of BMT CTN-0201 samples (2018) (1)
Analysis of BMT CTN-0201 and -0901 samples did not reproduce the reported association between recipient REG3A rs7588571 and chronic GVHD (2018) (1)
Role and Timing of Hematopoietic Cell Transplantation for Myelodysplastic Syndrome (2010) (1)
Impact of HLA matching on hematopoietic cell transplants from unrelated donors. (2000) (1)
Young is better if enough (2001) (1)
Sole Upfront Therapy with Beclomethasone and Budesonide for Upper Gastrointestinal Acute Graft-versus-Host Disease (2020) (1)
A Novel Reduced Toxicity Preparative Regimen For Hematopoietic Cell Allografting Combining Pentostatin (Nipent®) And Targeted Doses Of Intravenous Busulfan (Busulfex®) With Or Without Rituximab (PB ± R) Using CD4-Guided Immune Suppression: Preliminary Results Of An Ongoing Prospective Trial (2010) (1)
Three-year outcomes in recipients of mismatched unrelated bone marrow donor transplants using post-transplant cyclophosphamide: follow-up from a National Marrow Donor Program-sponsored prospective clinical trial. (2022) (1)
Fludarabine and Targeted Busulfan Is Safe and Effective Conditioning Before Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia in First Remission (2011) (1)
Retransplantation of marrow and hematopoietic stem cells from normal donors (1997) (1)
Unrelated donor marrow transplantation for chronic myeloid leukemia (CML) (1996) (1)
Allogeneic bone marrow transplantation for patients with hematologic malignancies. (1991) (1)
Large Scale Ex Vivo Expansion of γδ T cells Using Artificial Antigen-presenting Cells (2020) (1)
Multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic transplantation for high-risk multiple myeloma: Results of the BMT CTN 1302 Trial. (2022) (1)
New sources for argument: do HLA-C and HLA disparity in adult double umbilical cord blood transplants predict outcomes? (2016) (1)
CD4 Treg and CD4 Tcon Utilize Distinct TCR Vbeta Repertoires in Response to Alloantigen (2015) (1)
Factors Affecting Lymphocyte Collection Efficiency and Manufactured Product Specification during Leukapheresis for Diffuse Large B Cell Lymphoma Patients Treated with Commercial Tisagenlecleucel (2020) (1)
Maximally Tolerated Busulfan Area Under the Concentration-Time Curve (AUC) In Combination with Fludarabine as Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. (2010) (1)
Hematopoietic transplantation from adult unrelated donors (2003) (1)
P442 – Correlation of risk of acute graft-versus-host disease (GVHD) with donor-recipient mismatching for HLA-DQB1 alleles in unrelated donor (URD) transplantation (1996) (1)
T-Bet Is Critical for the Development of Acute Graft-Versus-Host Disease By Regulating Hematopoietic Antigen Presenting Cells (2014) (1)
A Phase I/II Trial Evaluating the Use of a Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients with Acute Graft Versus Host Disease (2013) (1)
marrow from unrelated donors: the effect of donor age Donor characteristics as risk factors in recipients after transplantation of bone (2013) (1)
Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd (2011) (1)
Fludarabine and Melphalan Results in Fewer Relapses Compared to Fludarabine and Targeted Busulfan in Patients Receiving Reduced Intensity Conditioning for AML and MDS (2016) (1)
33: Similar Graft-Versus-Leukemia Effect Using Matched Unrelated Donors, Compared to HLA-Identical Siblings for Hematopoietic Stem Cell Transplantation (2008) (1)
Separation of Graft-Versus-Host Disease and Graft-Versus-Leukemia Effects by Targeting T-Bet and RORγt Transcription Factors (2010) (1)
ELN 2017 Risk Classification Predicts Survival of AML Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation (2019) (1)
85: CD28 Controls Differentiation of Regulatory T Cells From Naive CD4 T Cells (2008) (1)
Human CD83 Targeted Chimeric Antigen Receptor T Cell for the Prevention of Graft Versus Host Disease and Treatment of Myeloid Leukemia (2019) (1)
Genetic and Pharmacologic Inhibition of PKCθ and PKCα Prevents Acute Gvhd While Sparing GVL Activity in Mice. (2012) (1)
Additive effects of anti-CD3 and anti-CD28 prolongation of allogeneic skin graft survival. (2001) (1)
Sympathectomy protects denervated skin from graft-versus-host disease. (2007) (1)
116: Determining Final Apheresis Volume for Hematopoietic Progenitor Cell (HPC) Collection Based on Intra-Procedural Sampling (2008) (1)
Predicting relevant immunogenetic disparities. (2016) (0)
Hypo-Albuminemia at Day+90 after Allogeneic Hematopoietic Cell Transplantation for Lymphoid Malignancies Independently Predicts for Inferior Overall Survival and Higher Non-Relapse Mortality (2015) (0)
T-cell costimulation in graft-versus-host disease and graft-versus-leukemia effect (2013) (0)
The Effect of Mycophenolate Mofetil Dose per Kilogram on Outcomes of Haploidentical Donor Peripheral Blood Stem Cell Transplant with Post-Transplant Cyclophosphamide (2023) (0)
High Frequency of Alloantigen-Specific T-Regs in Human Blood Allow Rapid Ex Vivo Expansion for Adoptive Therapy (2011) (0)
Long–Term Survival of Allogeneic Transplantation(Allo SCT) In Selected Patients with Multiple Myeloma (MM): Disease Free Survival at Two Years May Indicate Long Term Survival (2009) (0)
Effectiveness of Unrelated Donor Allogeneic Hematopoietic Cell Transplantation: Results of a Donor Vs. No Donor Analysis (2012) (0)
Phenotypic Analysis Of Multiple Myeloma Cell Progenitors (2010) (0)
Mediated by CD 8 Donor T Cells Severity of Graft-versus-Host Disease Alloantigen Affinity and CD 4 Help Determine (2006) (0)
A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease (2021) (0)
Fine-tuning alloreactivity against HLA-DP to control leukemia with tolerable graft-versus-host disease (2022) (0)
The role of HLA-DPB1 disparity in the development of acute graft-versus-host disease (GVHD) following unrelated marrow transplantation (1992) (0)
Photodynamic purging of immunoreactive T cells: the magic bullet? (2002) (0)
Increased Number of Prior Therapies and/or Use of Mismatched Unrelated Donors Adversely Affect Allogeneic Hematopoietic Cell Transplantation (alloHCT) Outcomes in Relapsed/Refractory Hodgkin Lymphoma (HL) (2013) (0)
A Phase 2 Study of Bortezomib Plus High-Dose Melphalan Conditioning for Autologous Hematopoietic Cell Transplantation in Multiple Myeloma (2012) (0)
single-center study disease after marrow transplantation from HLA-matched siblings: a methylprednisolone for the prevention of acute graft-versus-host Tacrolimus (FK506) alone or in combination with methotrexate or (2011) (0)
Allogeneic hematopoietic stem cell transplantation for myeloﬁbrosis (2003) (0)
HLA Typing in Support of Hematopoietic Cell Transplantation from Unrelated Donors (2013) (0)
Body Composition Predicts Survival in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Recipients (2015) (0)
IL-12/23p40 Neutralization in Combination with Sirolimus for Prevention of Acute Graft Vs. Host Disease (2015) (0)
Age Is the Strongest Independent Prognostic Factor in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: Moffitt Cancer Center Experience (2008) (0)
The Incidence of Venous Thromboembolism (VTE) in 892 Allogeneic Hematopoietic Cell Transplant (allo-HCT) Recipients ( A single institution study comparison of VTE incidence with sirolimus versus non-sirolimus-based GVHD prophylaxis) (2015) (0)
Th17 Lymphocytes In Human Gvhd Target Tissues Are Associated With Disease Severity and Refractoriness To Systemic Glucocorticoid Therapy (2013) (0)
Bortezomib Partially Overcomes TNF-Related Apoptosis Inducing ligand/Apo-2L (TRAIL/Apo-2L) Environment Mediated-Drug Resistance (EM-DR). (2004) (0)
Chronic Graft versus Host Disease: Interdisciplinary Management: Spectrum of Chronic Graft versus Host Disease in Unique Clinical Situations: The Role of Stem-Cell Source Including Cord Blood Stem Cells, Reduced-Intensity Conditioning, and Donor Leukocyte Infusions (2009) (0)
Bortezomib Targets Stroma-Mediated APO2l/Trail Apoptosis Resistance In Multiple Myeloma (2009) (0)
Autologous Stem Cell Transplantation (ASCT) In Patients Aged ≥65 Years With Multiple Myeloma: Moffitt Cancer Center Experience (2009) (0)
New Strategies for Fungal Infections after Hematopoietic Cell Transplantation : Prevention or Preemption ? (2007) (0)
MechanismsEstablished Melanoma through Distinct Elicits Antitumor Immunity against Adoptive Transfer of Tc1 or Tc17 Cells (2013) (0)
Hypoalbuminemia (< 3.0 g/dl) and Poor Karnofsky Performance (KPS<80) at Day +90 Are Independent Predictors of Worse Non-Relapse Survival (NRS) and Overall Survival (OS) in Adult Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Recipients: Results of a Multivariable Analysis (2009) (0)
Evaluation Of Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes Of One Hundred Thirty-Two Patients With Myelodysplastic Syndrome (MDS) Or Chronic Myelomonocytic Leukemia (CMML) Up To Age Seventy-Five and The Effect Of Pre-Transplant 5-Azacitidine (2013) (0)
Primary Plerixafor Mobilization In Autologous Hematopoietic Cell Transplant Candidates At High Risk For Mobilization Failure (2010) (0)
Antigen-Dependent Suppression of Graft Versus Host Disease by Foxp3- Induced Regulatory T Cells in Transplantation. (2005) (0)
First-line hypomethylating agents for patients with high risk chronic myelomonocytic leukaemia. (2021) (0)
184: Phase I Study of Bortezomib, (BTZ) followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL) (2008) (0)
Impact of Obesity and Chemotherapy Dosing on Allogeneic Hematopoietic Cell Transplant Outcomes for Myelodysplastic Syndrome (MDS) (2023) (0)
Donor γδ T Cells Influence Immune Escape and Relapse of Acute Myeloid Leukemia (AML) after Allogeneic Hematopoietic Cell Transplantation (HCT) (2023) (0)
Apheresis of Hematopoietic Progenitor Cell (HPC) From Allogeneic Donors ≥60 Years of Age. (2009) (0)
Ex vivo expansion of antigen specific Human Regulatory T-cells for the prevention or treatment of Graft-vs.-Host Diseases (145.26) (2010) (0)
Allogeneic Hematopoietic Cell Transplant Outcomes for Chronic Myelomonocytic Leukemia: Single Center Experience (2021) (0)
Hematopoietic Stroma Confers Resistance to Immune Control by TRAIL in Multiple Myeloma through Induction of FLIP. (2006) (0)
Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Older Patients (2021) (0)
Does HLA-C Matching Predict the Engrafting Unit in Double Umbilical Cord Blood Transplants?: A Single Institution Retrospective Analysis (2014) (0)
Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Bone Marrow: A Prespecified Analysis from the Phase III BMT CTN Protocol 0201 (2016) (0)
Microenvironment confers resistance to TRAIL mediated apoptosis (2005) (0)
A Phase 2 Study of High-Dose Melphalan Plus Bortezomib (Mel/Vel) Conditioning Followed By Autologous Hematopoietic Cell Transplantation in Myeloma (2014) (0)
Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant Outcomes for Acute Myeloid Leukemia (2022) (0)
Predictors of Non-Relapse Mortality Among Patients Treated with Sirolimus- Vs. Non-Sirolimus-Containing Immune Suppression for Graft-Versus-Host Disease Prevention (2016) (0)
Survival Advantage of the Addition of Cell Therapy to Chemotherapy in Adult Patients with Relapsed AML After Allogeneic Hematopoietic Cell Transplantation (2013) (0)
Environmental Mediated-Immune Resistance (EM-IR) to APO2L/TRAIL Mediated Apoptosis. (2007) (0)
Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML) (2022) (0)
Thrombopoietin and the mysteries of plasmacytoid dendritic cells (2004) (0)
Pharmacokinetically Targeted Intravenous Busulfan Combined with Fludarabine (BuFlu) as Conditioning Prior to Allogeneic Peripheral Blood Hematopoietic Cell Transplant: Pretransplant Predictors of Outcomes. (2009) (0)
Phase II Multicenter Study of Ofatumumab in Combination with Glucocorticoids As a Primary Therapy for Chronic Graft Versus Host Disease (2020) (0)
Alive in continuous remission Alive after relapse Transplant deaths ’ Causes of Death Relapse Graft failure and infection Without GVHD CMV pneumonia Other infection Hemorrhage VOD of liver CMV pneumonia Other infection Pulmonary failure With chronic GVHD Infection CMV pneumonia (2003) (0)
Advances in Allogeneic Hematopoietic Cell Transplantation: Progress in Transplantation Technology and Disease‐Specific Outcomes (2011) (0)
Human pSTAT3-Inhibited Itregs Prevent Gvhd, Maintain Anti-Leukemia Immunity, and Increase Their Potency after Metabolic Reprogramming (2020) (0)
Outcomes of Hematopoietic Cell Transplantation in Acute Promyelocytic Leukemia – a Single Institution Experience (2020) (0)
transplantation superior to HLA-identical siblings for hematopoietic stem cell The graft-versus-leukemia effect using matched unrelated donors is not (2011) (0)
C-FLIP Expression Determines Low Sensitivity Of Type 17 T Helper Cells To Activation-Induced Cell Death (2009) (0)
Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia: Comparison of Survival in Patients With an Available Donor Compared to Patients Without a Donor in Patients Up to Age 75 (2011) (0)
Evaluation of 243 Patients with Myelodysplastic Syndrome (MDS) Referred for Hematopoietic Cell Transplant (HCT) Including Donor Availability and HCT Outcomes. (2009) (0)
Phase I/II Trial of High-Dose Melphalan (M) and Topotecan (T) Followed by Autologous Stem Cell Rescue in Patients ≤ 60 and > 60 Years of Age with Multiple Myeloma (MM). (2007) (0)
Survival of Older Patients with AML and MDS after Allogeneic Hematopoietic Transplantation Is Best Determined By Combining Disease Risk and Comorbidity Indices (2019) (0)
Graft-Versus-Host Reaction T Cells in the + Antigen-Specific CD 8 Visualization , Fate , and Pathogenicity of Anasetti (1999) (0)
334: Cd18 separates GVHD and GVL effect (2007) (0)
donors graft-versus-host disease after marrow transplantation from unrelated methotrexate and cyclosporine for prophylaxis of acute Phase 3 study comparing methotrexate and tacrolimus with (2011) (0)
Ex vivo expansion of antigen specific Human Regulatory T-cells for the prevention or treatment of Graft-vs.-Host Diseases (2010) (0)
The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Rdsafe and BMT CTN 0201 (2021) (0)
Allogeneic Hematopoietic Cell Transplantation Using Fludarabine, Melphalan and Bortezomib (Flu/Mel/Vel) Conditioning For Consolidation Of VGPR Or CR In Myeloma (2013) (0)
Characterization of Clonotypic B Cell Progenitors in Bone Marrow of Multiple Myeloma Patients (2011) (0)
Administration of Rituximab 375 Mg/m2 on Days +1 and +8 after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) Regimens for Patients with Advanced CD20+ Lymphoid Malignancies (2008) (0)
Autologous hematopoietic cell transplantation (HCT) for non-Hodgkin lymphoma (NHL) in patients over 60 years of age (2008) (0)
Marrow transplantation in cancer therapy. (1992) (0)
Prospective Cohort Study of Immune Suppression Taper and Discontinuation (2022) (0)
High Efficacy of Alloantigen-Specific Induced Regulatory T Cells in the Prevention of Acute Graft-Versus-Host Disease in Mice (2012) (0)
Myelodysplastic Syndrome : The Transplanter ’ s Quandaries (2008) (0)
Reduced Intensity Fludarabine/Melphalan Has Similar Survival to Myeloablative Fludarabine/Busulfan (Targeted) in Patients with AML and MDS (2017) (0)
Outcomes of Hematopoietic Cell Transplantation in Acute Promyelocytic Leukemia - a Single Institution Experience (2019) (0)
Allogeneic Hematopoietic Cell Transplantation for Consolidation of Vgpr or Cr in Myeloma (2011) (0)
Distinct Role of Antigen-Specific Tc1 and Tc17 Cells in Tumor Eradication In Vivo (2011) (0)
Part by Regulating c-FLIP Apo2 Ligand/TRAIL in Multiple Myeloma in Bone Marrow Stroma Confers Resistance to (2008) (0)
Cells After Strong TCR Ligation CD28 Signal Enhances Apoptosis of CD8 T (2003) (0)
Incidence of Pneumocystis Jirovecii Infection and Duration of Prophylaxis After Allogeneic Stem Cell Transplantation (2013) (0)
Resistance of Th17 cells to Activation-Induced Cell Death (47.13) (2009) (0)
Beclomethasone and Budesonide Are Partially Effective As Sole Therapy for Isolated Gastro-Intestinal Gvhd (2014) (0)
Autologous hematopoietic cell transplantation (HCT) for Non-Hodgkins lymphoma (NHL) in patients over 60 years of age (2008) (0)
Prolonged Sirolimus Administration after Matched Related and Unrelated Allogeneic Hematopoietic Cell Transplantation Is Associated with Decreased Risk for Moderate-Severe Chronic Graft Vs. Host Disease (2014) (0)
Immunogenetics of allogeneic hematopoietic transplantation (1996) (0)
Clinical Impact of Cytokine Release Syndrome on Outcomes of Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide (2020) (0)
success of unrelated donor marrow transplantation High-resolution donor-recipient HLA matching contributes to the (2013) (0)
Comparison of Characteristics and Outcomes of Trial Participants and Non-participants: Example of Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0201 Trial (2015) (0)
Subject Index, Vol. 6, 1987 (1987) (0)
Abstract 4434: Selinexor and melphalan combination therapy for the treatment of multiple myeloma (2015) (0)
Updated Outcomes of Fludarabine/Melphalan/Bortezomib (Flu/Mel/Vel) Conditioning for Upfront Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma (2016) (0)
The Graying of Clinical Transplantation (2006) (0)
An International Multicenter Comparative Analysis of Tacrolimus Plus Sirolimus with or without Antithymocyte Globulin As Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation (2015) (0)
HLA-identical marrow transplantation in the leukemias without T-cell depletion. The Seattle Marrow Transplant Team. (1990) (0)
Anti-lymphocyte antibody crossmatch by flow microfluorimetry (FMF): Pretransplant testing of patient's serum and HLA nonidentical donor cells (1988) (0)
Inhibition of Human Dendritic Cell ER Stress Reduces Gvhd Without Impairing Tregs, NK Cells, or Anti-Tumor Ctl (2018) (0)
Prevention of Graft-Versus-Host Disease by HY-Specific Induced Tregs Through Activation-Dependent Manner, (2011) (0)
Targeted Iv Busulfan And Fludarabine Followed By Post-Allogeneic Hematopoietic Cell Transplantation Rituximab Demonstrate Encouraging Activity In High Risk CD20+Positive Lymphoid Malignancies Without Increased Infectious Complications (2010) (0)
Conditioning regimens in bone marrow transplantation (1991) (0)
Marrow grafting for acute leukemia (1990) (0)
Graft-Versus-Host Disease: A Prospective, Randomized Trial Cyclosporine or Cyclosporine Plus Methylprednisolone for Prophylaxis of (2011) (0)
disease in patients undergoing marrow transplants? What role for prednisone in prevention of acute graft-versus-host (2011) (0)
Safety and Efficacy of Fludarabine and PK-Targeted Intravenous Busulfan Before Allografting for Adult ALL (2009) (0)
CD40 Ligand Blockade Prevents Acute Gvhd: Results from a Multicenter Phase I-Ib Trial (2022) (0)
Chapter 105 – Unrelated Donor Hematopoietic Cell Transplantation (2018) (0)
Autoimmune Diseases : When Homeland Security Fails (2004) (0)
Sirolimus Yields High Response Rates in Hematopoietic Allograft Recipients with Steroid-Refractory Acute Graft-Versus-Host Disease. (2009) (0)
hematopoietic stem cell transplantation Cyclophosphamide metabolism , liver toxicity , and mortality following (2002) (0)
Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Older Versus Younger Patients (2020) (0)
Amino Acid Substitution At Peptide-Binding Pockets of HLA Class I Molecules Adversely Impacts Hematopoietic Cell Transplantation Outcomes (2012) (0)
Characterization of Clonal Pre-B Cell Progenitors of Plasma Cells In Multiple Myeloma (2010) (0)
Bortezomib Targets Stroma-Mediated APO2L/TRAIL Apoptosis Resistance in Multiple Myeloma. (2008) (0)
Chromosome-Positive Acute Lymphoblastic Leukemia Marrow Transplants From Unrelated Donors for Treatment of Philadelphia (2011) (0)
Measurable Residual Disease Outcompetes Cytogenetics in Predicting Leukemia Free Survival Following Allogeneic Stem Cell Transplantation Outcomes in Adults with Acute Lymphoblastic Leukemia (2022) (0)
Gene Deletions of 17p or 11q Are Independent Predictors of Decreased Progression-Free Survival and Overall Survival Following Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia (2012) (0)
Off-the-shelf TCR for graft-versus-leukemia without GVHD. (2018) (0)
Sirolimus Induces Complete Remission of Acute Graft-Versus-Host Disease Without Systemic Glucocorticoids (2011) (0)
Pre-Transplant Azacitidine and Allogeneic Hematopoietic Cell Transplant (HCT) Outcomes of One Hundred Fifty-Nine Patients up to Age Seventy-Five with Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (2014) (0)
Selection of DPB1 T-Cell Epitope Permissive Matching Likely for Patients with 10/10 Unrelated Donors (2015) (0)
Single Nucleotide Polymorphisms of Paneth Cell Antimicrobial Alpha Defensin-5 (DEFA5) are Associated with Acute Graft-Versus-Host Disease: Results From Analysis of BMT-CTN0201 Samples (2018) (0)
Graft-Versus-Leukemia Effect Is Equivalent in Recipients of Matched Sibling and Matched Unrelated Donor Conventional Hematopoietic Cell Transplant. (2007) (0)
Apheresis And Transplant Of Hematopoietic Progenitor Cells (HPC) From Allogeneic Donors ≥60 Years Of Age (2010) (0)
Selection of a marrow donor facilitated by the molecular characterization of a novel HLA-A30 allele (1992) (0)
Dynamic Changes and Impact of Myeloid Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice. (2012) (0)
Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide (2022) (0)
CD 8 T Cells Graft-versus-Host Disease Mediated by CD 4 Opposing Effects of ICOS on Claudio Anasetti (2006) (0)
Sirolimus, Tacrolimus and Antithymocyte Globulin Are Associated with Improved Overall Survival When Compared to Methotrexate, Tacrolimus and Antithymocyte Globulin in Mismatched Unrelated Allogeneic Hematopoietic Cell Transplantation (2014) (0)
IBMTR/ABMTR Newsletter-June 2004 (PDF) (2004) (0)
Targeted Intravenous Busulfan and Fludarabine Allogeneic Transplantation Conditioning in Acute Myeloid Leukemia. (2009) (0)
Controlling T Cell Differentiation and Acute Graft-versus-Host Disease through T-bet Is Critical for the Development of (2014) (0)
Mutated not activating IgG2 domain and these sequence-containing anti-CD3 antibody (1997) (0)
malignancies nonmyeloablative conditioning for patients with hematologic HLA-matched unrelated donor hematopoietic cell transplantation after (2013) (0)
Day 100 Levels of Blood Immune Cells Are Prognostic Biomarkers for Allogeneic Hematopoietic Stem Cell Transplant Outcomes: Results from BMT CTN 0201 (2017) (0)
ATG for the Prevention of Severe Acute Graft-Versus-Host Disease in Mismatched Unrelated Donor Hematopoietic Cell Transplantation (2011) (0)
Selecting donor recipients. (2009) (0)
Cell cycle control of T cell apoptosis induced by activation through the T cell antigen receptor. (1996) (0)
Tolerability and Outcomes of a Targeted Intravenous Busulfan and Fludarabine (T-BU/FLU) Conditioning Regimen for the Treatment De Novo and Secondary Acute Myeloid Leukemia (AML) (2009) (0)
Regulatory T CELLS Specific for Minor Histocompatibility Antigens (2013) (0)
New Guidelines Help Health Professionals Recognize and Manage Late Complications (2006) (0)
High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation Early during the Course of Disease Appears to Improve Outcomes of Patients T Cell Non-Hodgkin Lymphoma: Results of a Single-Institution Experience (2014) (0)
95: Autologous hematopoietic cell transplantation (auto-HCT) in chronic lymphocytic leukemia (CLL): Results of a systematic review (2007) (0)
Comparison of Sirolimus and Mycophenolate Mofetil as Salvage Treatment for Acute Graft-Versus-Host Disease (2011) (0)
Utility Of Revised International Prognostic Scoring System (R-IPSS) To Predict Outcome Of Myelodysplastic Syndromes (MDS) Patients After Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) (2013) (0)
Quality of Life in Patients Treated with Sirolimus and Tacrolimus for Prevention of Graft-Versus-Host Disease (2013) (0)
of April 15 , 2017 . This information is current as Part by Regulating c-FLIP Apo 2 Ligand / TRAIL in Multiple Myeloma in Bone Marrow Stroma Confers Resistance (2008) (0)
Marrow transplantation from unrelated donors iudt in patients with aplastic anemia (AA) who have failed immunosuppressive therapy (1996) (0)
Activated Human T Cells Anti-CD 3 Antibodies Induce Apoptosis of Non-Fc Receptor-Binding Humanized (2000) (0)
CD28 Regulates de novo Generation of Tregs through IL-2 in the Periphery (88.49) (2007) (0)
Efficient and Selective Prevention of Graft-Versus-Host Disease by Ag-Specific Induced Regulatory T Cells In Mice. (2010) (0)
IgG2 domains unmutated activators and anti-CD3 antibodies incorporating the same. (1997) (0)
Comparison of results from HLA identical unrelated donors or from partially HLA matched family members (1993) (0)
Low treatment related mortality and improved survival in allogeneic peripheral blood stem cell transplant: Targeted intravenous Busulfan combined with Fludarabine (tBuFlu) as conditioning regimen (2006) (0)
Allogeneic Hematopoietic Stem Cell Transplantation In Myelofibrosis: Single Center Experience (2010) (0)
Prospective Trial of Pre-Transplant 5-Azacitidine on Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndrome and CMML (2010) (0)
Impact of Splenomegaly in the Presence of Negative PET FDG Avidity on Allogeneic Hematopoietic Cell Transplant Outcomes in Patients with Lymphoid Malignancies (2015) (0)
Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia In Patients up to Age 75: Comparison of Survival In Patients with An Available Donor Compared to Patients without a Donor (2010) (0)
Assessment of a Disease Risk Index in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Fludarabine and Pharmacokinetically Dose-Targeted Intravenous Busulfan: Effect On Overall and Progression-Free Survival (2013) (0)
Plerixafor Use in Autologous Hematopoietic Cell Transplant Candidates at High Risk for Mobilization Failure (2011) (0)
High Frequency of Alloantigen-Specific Regulatory T-Cells In Human Blood Allow Rapid Ex Vivo Expansion for Adoptive Therapy. (2010) (0)
Donor and Graft Selection in Allogeneic Hematopoietic Cell Transplantation (2014) (0)
258: Voriconazole is Effective Prophylaxis for Aspergillus Invasive Fungal Infection (IFI) in Patients Receiving Glucocorticosteroid Therapy for GVHD after Allogeneic Transplantation (2008) (0)
Current Status of Allogeneic and Autologous Hematopoietic Stem Cell Transplantation in AML Management 9 (2010) (0)
Transplantation of hematopoietic stem cells from unrelated volunteer donors. (2000) (0)
Moffitt's ICE-T Fuels CAR-T Infrastructure Execution for Commercial Launch (2018) (0)
Purification and Expansion of Antigen-Specific Human Tregs for Clinical Application Using a Single Step CD25 Positive Selection (2012) (0)
Bortezomib Reverts Stroma-Mediated Resistant to APO2L/TRAIL in Multiple Myeloma. (2009) (0)
156: Treatment of Myeloid Malignancies in Elderly Patients with Fludarabine and Targeted Busulfan (t-Bu) and Allogeneic Hematopoietic Cell Transplantation (HCT) (2008) (0)
Pretransplant Factors That Influence Intravenous Busulfan Kinetics in Adult Patients. (2009) (0)
Tregs Specific for Minor Histocompatibility Antigens (2012) (0)
comparing cyclosporine plus prednisone versus prednisone alone Therapy for chronic graft-versus-host disease: a randomized trial (2013) (0)
Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PB±R) Using a Novel Principle of CD4-Guided Immune Suppression (2011) (0)
Antithymocyte Globulin Aplastic Anemia Conditioned by Cyclophosphamide Combined With Long-Term Follow-Up of Allogeneic Marrow Transplants in Patients With (2011) (0)
anemia (letter) Donor buffy coat cell infusion after marrow transplantation for aplastic (2011) (0)
Analysis) Transplants for Severe Aplastic Anemia (A 26-Year Retrospective Decreased Rejection and Improved Survival of First and Second Marrow (2013) (0)
64: Interleukin-6 and hematopoietic soluble factors confers resistance to trail mediated apoptosis (2007) (0)
Unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with poor risk, relapsed or refractory multiple myeloma (2004) (0)
Efficient And Selective Prevention Of Graft-Versus-Host Disease By Antigen-Specific TGFβ-Induced Regulatory T Cells (2008) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Claudio M. Anasetti?

Claudio M. Anasetti is affiliated with the following schools:

Claudio M. Anasetti's Academic­Influence.com Rankings

Claudio M. Anasetti's Degrees

Why Is Claudio M. Anasetti Influential?

Claudio M. Anasetti's Published Works

Published Works

What Schools Are Affiliated With Claudio M. Anasetti?

Claudio M. Anasetti's AcademicInfluence.com Rankings